Skip to main content

Genomic Health Comments on New FDA IVD Guidance

NEW YORK (GenomeWeb News) — Genomic Health said today that it has provided initial comment on the US Food and Drug Administration's draft guidance on "In Vitro Diagnostic Multivariate Index Assays."
Randy Scott, Genomic Health’s chairman and CEO said in a statement that the “draft guidance represents the first public discussion surrounding the agency's thinking about the regulation of certain laboratory-developed tests."
Genomic Health “plans to continue its ongoing dialogue with FDA regarding Oncotype Dx,” the firm’s RT-PCR-based breast cancer prognostic, which the company said went through multiple clinical trials among 2,600 patients.
Genomic Health has offered Oncotype Dx as a service through its CLIA-approved lab in Redwood City, Calif since 2004.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.